Juha O Rinne

Author PubWeight™ 98.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004 2.91
2 Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012 2.61
3 Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A 2010 2.32
4 Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 2008 2.24
5 Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008 2.19
6 The use of PET in Alzheimer disease. Nat Rev Neurol 2010 2.13
7 Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008 2.04
8 Binge drinking in midlife and dementia risk. Epidemiology 2005 1.61
9 Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 2005 1.58
10 The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging 2008 1.55
11 Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse 2007 1.46
12 Brain white matter expansion in human obesity and the recovering effect of dieting. J Clin Endocrinol Metab 2007 1.46
13 Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008 1.31
14 Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord 2002 1.31
15 Effects of working-memory training on striatal dopamine release. Science 2011 1.30
16 Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003 1.29
17 Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2008 1.15
18 Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging 2014 1.11
19 Altered dopamine D2 receptor binding in atypical facial pain. Pain 2003 1.10
20 C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 2009 1.10
21 Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage 2012 1.07
22 Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse 2015 1.05
23 Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006 1.05
24 Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev 2002 1.04
25 Mobile phone affects cerebral blood flow in humans. J Cereb Blood Flow Metab 2006 1.03
26 Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord 2004 1.03
27 Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 2005 1.02
28 Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002 1.01
29 Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med 2013 1.00
30 Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis 2008 0.98
31 Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med 2007 0.97
32 Effects of a 902 MHz mobile phone on cerebral blood flow in humans: a PET study. Neuroreport 2003 0.97
33 Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging 2012 0.96
34 Age-related loss of extrastriatal dopamine D(2) -like receptors in women. J Neurochem 2002 0.96
35 Midlife sleep characteristics associated with late life cognitive function. Sleep 2013 0.96
36 Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport 2004 0.94
37 Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med 2009 0.94
38 Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke 2004 0.93
39 Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging 2010 0.93
40 Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord 2012 0.92
41 Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging 2009 0.92
42 Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 2009 0.91
43 Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012 0.90
44 Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction. J Neurol Sci 2013 0.89
45 Expectation of caffeine induces dopaminergic responses in humans. Eur J Neurosci 2004 0.89
46 Midlife alcohol consumption and later risk of cognitive impairment: a twin follow-up study. J Alzheimers Dis 2010 0.89
47 Naming of newly learned objects: a PET activation study. Brain Res Cogn Brain Res 2005 0.87
48 Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data. Eur J Nucl Med Mol Imaging 2009 0.87
49 Whole-body distribution and metabolism of [N-methyl-11C](R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with positron emission tomography. Eur J Nucl Med Mol Imaging 2008 0.87
50 No association between the brain-derived neurotrophic factor 196 G>A or 270 C>T polymorphisms and Alzheimer's or Parkinson's disease. Folia Neuropathol 2006 0.87
51 A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009 0.86
52 Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta Neuropathol Commun 2014 0.86
53 Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study. J Cereb Blood Flow Metab 2013 0.86
54 Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab 2010 0.86
55 Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010 0.86
56 COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo. Mol Imaging Biol 2009 0.85
57 Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 2003 0.85
58 Midlife cardiovascular risk factors and late cognitive impairment. Eur J Epidemiol 2013 0.84
59 Acute hormonal changes following intravenous glucose challenge in lean and obese human subjects. Scand J Clin Lab Invest 2010 0.84
60 Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns. Neurosci Lett 2004 0.84
61 [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010 0.84
62 A rare mitochondrial DNA haplotype observed in Koreans. Hum Biol 2002 0.83
63 Visual object recognition deficits in early Parkinson's disease. Parkinsonism Relat Disord 2004 0.83
64 Brain oscillatory responses to an auditory-verbal working memory task in mild cognitive impairment and Alzheimer's disease. Int J Psychophysiol 2005 0.83
65 Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait. Mov Disord 2007 0.83
66 Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. Eur J Nucl Med Mol Imaging 2014 0.82
67 Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. Brain Res 2002 0.82
68 Carbon monoxide poisoning-induced nigrostriatal dopaminergic dysfunction detected using positron emission tomography (PET). Neurotoxicology 2010 0.81
69 Cerebral oxygen and glucose metabolism in patients with mitochondrial m.3243A>G mutation. Brain 2009 0.81
70 Brain function during multi-trial learning in mild cognitive impairment: a PET activation study. Brain Res 2007 0.81
71 Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function. Synapse 2008 0.81
72 Personality traits and striatal 6-[18F]fluoro-L-dopa uptake in healthy elderly subjects. Neurosci Lett 2002 0.80
73 Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography. Neuroimage 2013 0.80
74 Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009 0.80
75 1-11C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation. J Nucl Med 2008 0.80
76 Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment. Mult Scler 2011 0.79
77 GSM mobile phone radiation suppresses brain glucose metabolism. J Cereb Blood Flow Metab 2011 0.79
78 [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J Alzheimers Dis 2012 0.79
79 Absence of association between an intercellular adhesion molecule 1 gene E469K polymorphism and Alzheimer's disease in Finnish patients. Neurosci Lett 2003 0.78
80 Seasonality of striatal dopamine synthesis capacity in Parkinson's disease. Neurosci Lett 2012 0.78
81 Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother 2006 0.77
82 ¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. Eur J Nucl Med Mol Imaging 2014 0.77
83 No effects of short-term GSM mobile phone radiation on cerebral blood flow measured using positron emission tomography. Bioelectromagnetics 2011 0.77
84 Cerebral glucose metabolism in dizygotic twin pairs discordant for Alzheimer's disease. Dement Geriatr Cogn Disord 2007 0.77
85 Different brain activation patterns during production of animals versus artefacts: a PET activation study on category-specific processing. Brain Res Cogn Brain Res 2002 0.77
86 Regional cerebral glucose metabolism in monozygotic twins discordant for Alzheimer's disease. Dement Geriatr Cogn Disord 2003 0.77
87 Naming multiple objects: neural correlates as measured by positron emission tomography. Appl Neuropsychol 2003 0.77
88 Central executive function in mild cognitive impairment: a PET activation study. Scand J Psychol 2008 0.77
89 Reduced striatal dopamine synthesis capacity is associated with symptoms of depression in patients with de novo unmedicated Parkinson's disease. J Parkinsons Dis 2013 0.77
90 Neural correlates of naming newly learned objects in MCI. Neuropsychologia 2007 0.76
91 Learning and forgetting new names and objects in MCI and AD. Neuropsychologia 2009 0.76
92 Brain ¹⁸F-FDG and ¹¹C-PiB PET findings in two siblings with FTD/ALS associated with the C9ORF72 repeat expansion. Neurocase 2012 0.76
93 Shorter adult stature increases the impact of risk factors for cognitive impairment: a comparison of two Nordic twin cohorts. Twin Res Hum Genet 2011 0.76
94 Brain volumetric correlates of memory in early Parkinson's disease. J Parkinsons Dis 2013 0.76
95 A 90-year-old monozygotic female twin pair discordant for Alzheimer's disease. Neurobiol Aging 2003 0.76
96 Neuropsychological functions in variant Alzheimer's disease with spastic paraparesis. J Neurol Sci 2004 0.75
97 Boxing and Parkinson disease: a link or a myth? An 18F-FDOPA PET/CT study in retired Thai traditional boxers. Parkinsonism Relat Disord 2012 0.75
98 Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson's disease. J Neural Transm (Vienna) 2013 0.75
99 Brain Cholinergic Function and Response to Rivastigmine in Patients With Chronic Sequels of Traumatic Brain Injury: A PET Study. J Head Trauma Rehabil 2017 0.75
100 Cognitive decline and amyloid accumulation in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2012 0.75
101 The relationship between recognition memory for emotion-laden words and white matter microstructure in normal older individuals. Neuroreport 2016 0.75
102 Comparison of manual and automatic techniques for substriatal segmentation in 11C-raclopride high-resolution PET studies. Nucl Med Commun 2016 0.75
103 19F/18F exchange synthesis for a novel [18F]S1P3-radiopharmaceutical. J Labelled Comp Radiopharm 2013 0.75